Evaluation of Pharmacy Students' Perception of Opioid / Opiate Dependence
NCT03859778 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2034
Last updated 2019-05-24
Summary
The pharmacist in his professional activity may have to manage opioid dependent patients. This professional activity will result in the provision of opioid substitution treatment (OST), single-use syringes, harm reduction kits and a prevention advice for the reduction of toxicity and infection risks.
Since the 1990s, the consumption of OST has been steadily increasing. According to the OFDT (French Observatory of Drugs and Drug Addiction), the number of patients under OST is about 150 000 patients. Since high-dose buprenorphine is prescribed for approximately two-thirds of patients, it remains the most frequently prescribed OST in France.
Recently, a French association assisting drug users (ASUD - Auto-support des usagers de drogues) performed a study in Paris (20/07/2018 - 25/08/2018) to assess the delivery of opioid replacement therapies by community pharmacists. In this study, 71% of pharmacists refused to deliver opioid replacement therapies. The main reasons reported were security (56%) and activity saturation, meaning that pharmacists considered that they had too many patients using opioid drugs. In France, the refusal of a pharmacist to deliver drugs is a punishable offence. According to the Code of ethics of pharmacists, pharmacists must respect life and people without discrimination. Pharmacists have a low perception of patients suffering from opioid addiction. Another study performed by ASUD in 93 community pharmacies, showed that pharmacists used the term "toxicomaniacs" instead of "drug users". Most pharmacists had had a bad experience with drugs users, with physical and verbal aggressions. The conclusions of this study showed that pharmacists lacked knowledge of drug users and drug use. Pharmacists knew about harm reduction kits for opioid users (containing sterile syringes, needles, water, antiseptics, etc.) and had already opened them, but very few knew how to use them. More worryingly, some pharmacists did not understand the harm reduction strategies available It thus appears that community pharmacists have a difficult relationship with opioid-dependent patients, even though these pharmacists have received education in the management of addictions during their studies. Indeed, it can consider that these courses should help to better understand the addictive disease both in its nosological / semiological and therapeutic components. Thus, it would be interesting to evaluate the impact of addiction education on pharmacists' perception of opioid dependence. In this perspective, it would be interesting to focus on pharmacy students.
The objective of this study will be to evaluate the perception by pharmacy students of opioid dependent patients. Investigator would like to know if pharmacy students consider opioid addiction to be an illness and whether having taken education on drug use and addictions changes this perception.
Conditions
- Opioid-Related Disorders
Interventions
- OTHER
-
survey
French pharmacy students will be contacted by email thanks to the student associations and scolarity departments. Answer to the survey will be done online
Sponsors & Collaborators
-
UFR Pharmacie (Clermont-Ferrand)
collaborator UNKNOWN -
University Hospital, Clermont-Ferrand
lead OTHER
Principal Investigators
-
David BALAYSSAC · University Hospital, Clermont-Ferrand
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2019-01-14
- Primary Completion
- 2019-03-31
- Completion
- 2019-03-31
Countries
- France
Study Locations
More Related Trials
-
Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED)
NCT00723697 ·Status: COMPLETED
-
Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075
NCT03248947 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Pupillometry and Pain Thresholds Patients Substituted by Methadone and Buprenorphine
NCT01560442 ·Status: UNKNOWN
-
Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool
NCT05706311 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
OPAL: "Opiates and PhArmacoLogy"
NCT01847729 ·Status: COMPLETED
-
A Prospective Investigation of the Risks of Opioid Misuse, Abuse, and Addiction Among Patients Treated With Opioids for the Treatment of Chronic Pain
NCT02751762 ·Status: COMPLETED
-
A Study to Evaluate Unintended Prolonged Opioid Use
NCT04024397 ·Status: COMPLETED
-
Determining the Feasibility of Outpatient Parenteral Antibiotic Therapy for Persons Who Inject Opioids
NCT05300581 ·Status: COMPLETED ·Phase: NA
-
Prescription Opioid Effects in Abusers Versus Non-Abusers
NCT00158184 ·Status: COMPLETED ·Phase: PHASE2
-
Oxycodone User Registry (OUR)
NCT00978328 ·Status: COMPLETED
-
Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017 (d-Methadone)
NCT03637361 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing
NCT05307458 ·Status: UNKNOWN
-
PRescribing INterventions for Chronic Pain Via the Electronic Health Record Study - Current Opioid-User Population
NCT04601480 ·Status: COMPLETED ·Phase: NA
-
Effects of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sublingual and Intravenous Buprenorphine
NCT01854489 ·Status: COMPLETED ·Phase: PHASE4
-
A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse
NCT03033732 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment Outcomes Among Patients With Prescription Narcotic Drug Use Disorder
NCT03713983 ·Status: ACTIVE_NOT_RECRUITING
-
5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
NCT01549652 ·Status: COMPLETED ·Phase: NA
-
Sensory Outcomes in Active Substance Users
NCT06639438 ·Status: RECRUITING
-
Pupillary Unrest in Ambient Light, and Relationship to Opioid-Induced Respiratory Depression
NCT04301895 ·Status: COMPLETED ·Phase: PHASE1
-
Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use Disorder
NCT06086275 ·Status: COMPLETED ·Phase: PHASE1
-
Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice
NCT00007527 ·Status: COMPLETED ·Phase: PHASE4
-
Low-dose Buprenorphine Initiation for Opioid Use Disorder
NCT05450718 ·Status: RECRUITING ·Phase: PHASE4
-
A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users
NCT02218021 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7
NCT00000358 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.
NCT03389750 ·Status: COMPLETED ·Phase: PHASE2